外用钙调神经磷酸酶抑制剂的黑框警告：跳出框框思考。 - Suppr

Suppr

超能文献

The black box warning for topical calcineurin inhibitors: looking outside the box.

作者信息

Fonacier Luz, Charlesworth Ernest N, Spergel Jonathan M, Leung Donald Y M

机构信息

Winthrop University Hospital, State University of New York, Stony Brook School of Medicine, New York, USA.

出版信息

Ann Allergy Asthma Immunol. 2006 Jul;97(1):117-20. doi: 10.1016/S1081-1206(10)61381-6.

DOI:10.1016/S1081-1206(10)61381-6

PMID:16892793

Abstract

摘要

相似文献

The black box warning for topical calcineurin inhibitors: looking outside the box.

Ann Allergy Asthma Immunol. 2006 Jul;97(1):117-20. doi: 10.1016/S1081-1206(10)61381-6.

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001.

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.

J Allergy Clin Immunol. 2005 Jun;115(6):1249-53. doi: 10.1016/j.jaci.2005.04.006.

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62.

[Topical immune modulation and risk of cancer].

Ugeskr Laeger. 2009 Aug 24;171(35):2468-71.

Topical calcineurin inhibitors labeling: putting the "box" in perspective.

Arch Dermatol. 2006 Sep;142(9):1233-5. doi: 10.1001/archderm.142.9.1233.

Black box warning for topical calcineurin inhibitors and the death of common sense.

Dermatol Online J. 2006 Oct 31;12(6):2.

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

J Am Acad Dermatol. 2006 May;54(5):818-23. doi: 10.1016/j.jaad.2006.01.054.

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians.

Am J Clin Dermatol. 2007;8(4):189-94. doi: 10.2165/00128071-200708040-00001.

Association between exposure to topical tacrolimus or pimecrolimus and cancers.

Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.

引用本文的文献

Therapeutic effect of long-interval repeated subcutaneous administration of canine amniotic membrane-derived mesenchymal stem cells in atopic dermatitis mouse model.

BMC Vet Res. 2025 Feb 27;21(1):115. doi: 10.1186/s12917-025-04554-w.

Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.

Expert Rev Clin Pharmacol. 2023 Feb;16(2):119-131. doi: 10.1080/17512433.2023.2173172. Epub 2023 Feb 6.

EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus.

Int J Hematol. 2018 Sep;108(3):329-334. doi: 10.1007/s12185-018-2426-2. Epub 2018 Mar 7.

Atopic dermatitis and the atopic march: what is new?

J Allergy (Cairo). 2011;2011:279425. doi: 10.1155/2011/279425. Epub 2011 Sep 13.

The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Drug Saf. 2008;31(3):185-98. doi: 10.2165/00002018-200831030-00001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The black box warning for topical calcineurin inhibitors: looking outside the box.

作者信息

Fonacier Luz, Charlesworth Ernest N, Spergel Jonathan M, Leung Donald Y M

机构信息

Winthrop University Hospital, State University of New York, Stony Brook School of Medicine, New York, USA.

出版信息

Ann Allergy Asthma Immunol. 2006 Jul;97(1):117-20. doi: 10.1016/S1081-1206(10)61381-6.

DOI:10.1016/S1081-1206(10)61381-6

PMID:16892793

Abstract

摘要

相似文献

The black box warning for topical calcineurin inhibitors: looking outside the box.

Ann Allergy Asthma Immunol. 2006 Jul;97(1):117-20. doi: 10.1016/S1081-1206(10)61381-6.

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001.

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.

J Allergy Clin Immunol. 2005 Jun;115(6):1249-53. doi: 10.1016/j.jaci.2005.04.006.

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62.

[Topical immune modulation and risk of cancer].

Ugeskr Laeger. 2009 Aug 24;171(35):2468-71.

Topical calcineurin inhibitors labeling: putting the "box" in perspective.

Arch Dermatol. 2006 Sep;142(9):1233-5. doi: 10.1001/archderm.142.9.1233.

Black box warning for topical calcineurin inhibitors and the death of common sense.

Dermatol Online J. 2006 Oct 31;12(6):2.

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

J Am Acad Dermatol. 2006 May;54(5):818-23. doi: 10.1016/j.jaad.2006.01.054.

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians.

Am J Clin Dermatol. 2007;8(4):189-94. doi: 10.2165/00128071-200708040-00001.

Association between exposure to topical tacrolimus or pimecrolimus and cancers.

Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.

引用本文的文献

Therapeutic effect of long-interval repeated subcutaneous administration of canine amniotic membrane-derived mesenchymal stem cells in atopic dermatitis mouse model.

BMC Vet Res. 2025 Feb 27;21(1):115. doi: 10.1186/s12917-025-04554-w.

Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.

Expert Rev Clin Pharmacol. 2023 Feb;16(2):119-131. doi: 10.1080/17512433.2023.2173172. Epub 2023 Feb 6.

EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus.

Int J Hematol. 2018 Sep;108(3):329-334. doi: 10.1007/s12185-018-2426-2. Epub 2018 Mar 7.

Atopic dermatitis and the atopic march: what is new?

J Allergy (Cairo). 2011;2011:279425. doi: 10.1155/2011/279425. Epub 2011 Sep 13.

The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Drug Saf. 2008;31(3):185-98. doi: 10.2165/00002018-200831030-00001.